Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation study of PF-3512676 in advanced malignancies
NCT00043368Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2002
- Primary completion
- Jun 2007
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 2
01
Overview
A Phase 2 trial of agatolimod in melanoma, breast cancer, renal cell carcinoma (RCC), T-cell lymphoma, non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Sep 2002; status: completed.
02
Drugs
agatolimod
03
Conditions
melanomabreast cancerrenal cell carcinoma (RCC)T-cell lymphomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00043368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043368.